# CF PharmTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cf-pharmtech

- Industry: Pharmaceuticals
- Headquarters: Wuxi, China
- Website: www.cfpharmtech.com
- Total disclosed funding: $206M
- Latest round: Series F (Jul 2, 2020)
- Investors on record: 25

## About

Founded in 2007 and based in Wuxi, China, CF PharmTech, Inc.is a high-tech pharmaceutical company focused on developing pulmonary drug delivery and other drug delivery technologies, targeting domestic and international markets. In October 2025, CF PharmTech, Inc. raised HKD 607.7 million in an IPO, selling 41.2 million shares at HKD 14.75 apiece on the Hong Kong Stock Exchange under the ticker symbol "2652".

The company's pipeline covers a full range of respiratory products, addressing high-needs clinical areas such as asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The company boasts four R&D and production platforms for inhaled products: metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers and nasal sprays.

The company generates revenue by doing research, development, production and sales of its products and other related services.

## Funding rounds

- Series F, Jul 2, 2020, $51M — GP Capital, China International Capital Corporation, Passion Capital, YuanMing Capital, Watson Capital, Zhongjin Qiyu (Suzhou) Equity Investment Fund Management, BioTrack Capital, Hengxu Capital
- Series E, Jan 2, 2020, $90M — GTJA Investment Group, Oriza Holdings, New Alliance Capital, CMB International Asset Management, CoStone Capital, Everest VC, Finnova Capital, Junxin Investment, Suzhou Xiangcheng Fund
- Series D, Aug 28, 2017, $65M — CCB International Asset Management, CS Capital, Xin Ding Capital, YuanMing Capital, Beijing Heyutz Investment Management, Zhuhai Longmen Capital Management, Le Jin Capital, WIM Asset Management, Irse Capital

## Investors

- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series D
- CS Capital — Series D
- Xin Ding Capital (https://capitalatlas.ai/funds/xin-ding-capital) — Series D
- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Series D, Series F
- Beijing Heyutz Investment Management (https://capitalatlas.ai/funds/beijing-heyutz-investment-management) — Series D
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series D
- Le Jin Capital — Series D
- WIM Asset Management — Series D
- Irse Capital — Series D
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series E
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series E
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series E
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series E
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series E
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series E
- Finnova Capital (https://capitalatlas.ai/funds/finnova-capital) — Series E
- Junxin Investment — Series E
- Suzhou Xiangcheng Fund (https://capitalatlas.ai/funds/suzhou-xiangcheng-fund) — Series E
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series F
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series F
- Passion Capital — Series F
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series F
- Zhongjin Qiyu (Suzhou) Equity Investment Fund Management (https://capitalatlas.ai/funds/zhongjin-qiyu-suzhou-equity-investment-fund-management) — Series F
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series F
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series F